Literature DB >> 1904350

Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris.

J H Jansson1, T K Nilsson, B O Olofsson.   

Abstract

The value of measurements of the fibrinolytic factors, tissue plasminogen activator and plasminogen activator inhibitor, for predicting death and non-fatal cardiovascular events was studied in 213 consecutive patients with angiographically documented coronary artery disease. In the course of 4-year follow-up, 47 patients (22.1%) had at least one cardiovascular event. We found the incidence of cardiovascular events to be positively associated with high tissue plasminogen activator antigen concentration, in addition to previous myocardial infarction, low ejection fraction, hypertension, high body mass index and high triglyceride levels. Cholesterol was not found to be associated with cardiovascular events. A high concentration of tissue plasminogen activator antigen thus implies an increased risk of cardiovascular events in patients with severe angina pectoris.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1904350     DOI: 10.1093/oxfordjournals.eurheartj.a059862

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  13 in total

Review 1.  Angiotensin converting enzyme inhibitors--do they have an anti-ischemic action?

Authors:  J D Rutherford
Journal:  Trans Am Clin Climatol Assoc       Date:  1996

Review 2.  Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease.

Authors:  D de Bono
Journal:  Br Heart J       Date:  1994-06

Review 3.  Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?

Authors:  G Christ; K Kostner; M Zehetgruber; B R Binder; D Gulba; K Huber
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

4.  Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction.

Authors:  J H Jansson; K Boman; T K Nilsson
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 5.  Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.

Authors:  A J Wagstaff; J C Gillis; K L Goa
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

6.  von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction.

Authors:  J H Jansson; T K Nilsson; O Johnson
Journal:  Heart       Date:  1998-10       Impact factor: 5.994

7.  Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis.

Authors:  S Wållberg-Jonsson; G H Dahlén; T K Nilsson; M Rånby; S Rantapää-Dahlqvist
Journal:  Clin Rheumatol       Date:  1993-09       Impact factor: 2.980

8.  The influence of acute-phase levels of haemostatic factors on reperfusion and mortality in patients with acute myocardial infarction treated with streptokinase.

Authors:  Johan B Nilsson; Kurt Boman; Jan-Håkan Jansson; Torbjörn Nilsson; Ulf Näslund
Journal:  J Thromb Thrombolysis       Date:  2007-08-25       Impact factor: 2.300

9.  The long-term effects of metoprolol and epanolol on tissue-type plasminogen activator and plasminogen activator inhibitor 1 in patients with ischaemic heart disease.

Authors:  R A Wright; A M Perrie; F Stenhouse; K G Alberti; R A Riemersma; I R MacGregor; N A Boon
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

10.  von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death.

Authors:  J H Jansson; T K Nilsson; O Johnson
Journal:  Br Heart J       Date:  1991-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.